3SBio Inc.
1530
Rank in Stocks
#3611
Operating as an investment holding company, 3SBio Inc. specializes in the full... Operating as an investment holding company, 3SBio Inc. specializes in the full lifecycle of biopharmaceutical products within the People's Republic of China, encompassing research, development, manufacturing, marketing, and sales. Its diverse portfolio addresses a range of medical needs. Key therapeutic agents include TPIAO, a recombinant human thrombopoietin for chemotherapy-induced and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; and recombinant human erythropoietins EPIAO and SEPO, along with Aiyishu, to combat various forms of anemia. In oncology, Cipterbin is used for HER2-positive metastatic breast cancer in combination with chemotherapy. Intefen, a recombinant human interferon, targets lymphatic or hematopoietic malignancies and viral infections, while Inleusin, a human interleukin-2, treats renal cell carcinoma, melanoma, and thoracic fluid build-up. The company also offers Mandi for male alopecia and alopecia areata; Xenopax to prevent acute rejection post-renal transplant; Byetta for glycemic control in type 2 diabetes patients; and Qiming Keli for retinopathy linked to type 2 diabetes. SPARIN, an injectable low-molecular-weight heparin calcium, serves in the prophylaxis and treatment of deep vein thrombosis, and prevents clotting during hemodialysis. Beyond its core pharmaceutical activities, 3SBio Inc. provides additional services such as trading, project management and consultation, technology, and agricultural support. The company maintains strategic alliances with numerous prominent organizations, including AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and the Dana–Farber Cancer Institute. Established in 1993, its headquarters are situated in Shenyang, People's Republic of China.
Share Price
$1.87
Market Cap
$4.67B
Change (1 day)
-0.82%
Change (1 year)
-49.10%
Country
CN
Trade 3SBio Inc. (1530)
Category
Healthcare
P/E ratio for 3SBio Inc. (1530)
P/E ratio as of October 2026 TTM: 3.67
According to 3SBio Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 3.67. At the end of 2023 the company had a P/E ratio of 10.91.
P/E ratio history for 3SBio Inc. from 2012 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | 3.67 | -45.32% |
| 2024 | 6.72 | -38.43% |
| 2023 | 10.91 | 10.70% |
| 2022 | 9.86 | 15.05% |
| 2021 | 8.57 | -56.24% |
| 2020 | 19.58 | -16.67% |
| 2019 | 23.49 | 23.65% |
| 2018 | 19.00 | -45.10% |
| 2017 | 34.61 | 44.58% |
| 2016 | 23.94 | -38.66% |
| 2015 | 39.02 | -21.43% |
| 2014 | 49.66 | -66.34% |
| 2013 | 147.55 | 1,190.30% |
| 2012 | 11.44 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 28.78 | 683.31% |
US
|
|
| -28.36 | -871.78% |
US
|
|
| -24.57 | -768.60% |
AU
|
|
| - | - |
CH
|
|
| 30.33 | 725.44% |
NL
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.